Methylation As A Risk And Prognostic Factor For Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$594,913.00
Summary
DNA methylation is a process playing critical roles throughout life by altering the expression of genes. This study aims to investigate the potential use of methylation as marker of risk and early diagnosis of breast cancer in women with no clinical evidence of disease and marker of prognosis and response to treatment in breast cancer cases.
Statistical Analysis Of An International 10 Year Prospective Family Study Of Gene-environment Interactions On Risk Of Female Breast Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$450,198.00
Summary
This study will provide new and credible information on how the effects of environmental and lifestyle factors on breast cancer risk depend on a woman's underlying genetic susceptibility using a large, international 10 year prospective family study.
Determining The Natural History Of Localized High-risk Melanoma And Risk Factors For Melanoma Metastasis
Funder
National Health and Medical Research Council
Funding Amount
$103,980.00
Summary
This PhD thesis aims to describe 2-year survival rates of patients with localised melanoma. We will investigate risk factors and patterns of melanoma spread in patients with high-risk localised lesions. Risk factors for developing ulcerated versus non-ulcerated melanomas will be explored. We aim to describe support service use in melanoma patients in rural, regional and urban areas in Queensland.
Risk Of Recurrence After Diagnosis Of Invasive Breast Cancer By Molecular Subtype As Defined By ER, PR And Her2 Status
Funder
National Health and Medical Research Council
Funding Amount
$500,622.00
Summary
Breast cancer is a heterogeneous disease. Molecular subtypes have been identified that differ in terms of prognosis and response to treatment. This study aims to estimate recurrence free survival of breast cancer by molecular subtypes in a population-based sample of Australian women. The results will assist clinicians to guide their therapeutic decisions and will inform women about their anticipated outcome after diagnosis of breast cancer.
Who To Treat, When To Treat And How To Treat Prostate Cancer: Generating Evidence To Guide Prostate Cancer Treatment Decisions
Funder
National Health and Medical Research Council
Funding Amount
$408,768.00
Summary
There is considerable uncertainty about which treatments lead to better outcomes for men with prostate cancer and whether treatment is always necessary. This project will compare different treatment options for prostate cancer, including active surveillance, to determine which offers the best chance of survival and least harm to men’s physical and mental wellbeing. It will also explore whether some men who do not receive active treatment (healthy older men) would benefit if they did.
IMPROVE - Investigating Medication Re-Purposing To Reduce Risk Of OVarian Cancer And Extend Survival
Funder
National Health and Medical Research Council
Funding Amount
$430,196.00
Summary
Ovarian cancer is the 6th most common cause of cancer death in women and the proportion of women who die from their disease has not improved substantially over time. This large-scale study will use de-identified data from the Pharmaceutical Benefits Scheme, the Australian Cancer Database and the National Death Index to investigate whether medications commonly used for other conditions can help decrease the risk of ovarian cancer developing or improve survival from ovarian cancer after diagnosis.
The Ovarian Cancer Prognosis And Lifestyle (OPAL) Study: Long-term Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$871,657.00
Summary
Ovarian cancer affects 1500 women each year in Australia and 5-year survival is <45%. Affected women thus face a poor prognosis and often ask what they can do to improve this. There is no direct evidence whether a woman’s lifestyle might influence her outcomes, although data from breast cancer suggest this is possible. The OPAL Study is following 960 women with ovarian cancer to identify whether lifestyle is associated with long-term survival to provide evidence for women with this disease.
Improving Outcomes From Ovarian Cancer: Building The Evidence To Help Women Help Themselves
Funder
National Health and Medical Research Council
Funding Amount
$1,839,772.00
Summary
Ovarian cancer affects 1300 women each year in Australia and 5-year survival is <45%. Women with this cancer thus face a poor prognosis and many ask what they can do to improve this. There is no direct evidence whether a woman’s lifestyle might influence her outcomes, although data from breast cancer suggest this is possible. The OPAL Study will follow 1200 women with ovarian cancer to identify whether lifestyle is associated with survival to provide guidance for women with this disease.
Ovarian and endometrial cancer affect >3,200 women each year in Australia and 3 or 4 women die from these cancers every day. The overall aim of my program of research is to reduce the burden of these cancers in future generations of Australian women by increasing our understanding of (i) what causes them, (ii) how we can optimise patient management to enhance patient outcomes and (ii) how lifestyle changes might improve quality and life and survival, for women who are diagnosed with them.
Quantifying And Understanding Spatial Inequalities In Cancer Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$443,946.00
Summary
Outcomes for people with cancer depend on where they live; typically poorer in rural and socio-economically disadvantaged areas. However we know very little about why these inequalities exist. My proposed program of research develops and applies emerging statistical and spatial techniques to a unique set of registry and research data to examine the contribution of various individual- and area-level factors to cancer outcomes; increasing our capacity to intervene to reduce these inequalities.